1-5 of 5
Margit Schmidt, PhD
Close
Sort by
Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Andreas Viardot, MD, Mariele Goebeler, MD, Richard Noppeney, MD, Stefan W. Krause, MD, Stefan Kallert, MD, Barbara Ferstl, MD, Andreas Mackensen, Kathrin Rupertus, MD, Martin Soekler, MD, Lothar Kanz, MD, Stefan Knop, MD, Max S. Topp, MD, Jurgen Scheele, MD, PhD, Dirk Nagorsen, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Margit Schmidt, PhD, Peter Kufer, MD, Martin Libicher, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2011) 118 (21): 1637.
https://doi.org/10.1182/blood.V118.21.1637.1637
Published: 2011
Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Max S Topp, Gerhard Zugmaier, MD, Nicola Goekbuget, MD, Svenja Neumann, MD, Heinz-August Horst, MD, Thorsten Raff, MD, Monika Brueggemann, MD, Michael Kneba, MD, Andreas Viardot, MD, Mathias Schmid, MD, Markus Schaich, MD, Matthias Stelljes, MD, Mariele Goebeler, MD, Heike Pfeiffer, MD, Oliver Ottmann, MD, Thomas Burmeister, MD, Evelyn Degenhard, Margit Schmidt, PhD, Jürgen Scheele, MD, PhD, Hermann Einsele, MD, Peter Kufer, MD, Matthias Klinger, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 174.
https://doi.org/10.1182/blood.V116.21.174.174
Published: 2010
Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 2880.
https://doi.org/10.1182/blood.V116.21.2880.2880
Published: 2010
Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD
Journal: Blood
Blood (2008) 112 (11): 1926.
https://doi.org/10.1182/blood.V112.11.1926.1926
Published: 2008
Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD
Journal: Blood
Blood (2008) 112 (11): 267.
https://doi.org/10.1182/blood.V112.11.267.267
Published: 2008